CD137/FAP agonist
CD137/FAP agonist
Search
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
Do you take periodontal disease in dogs seriously? We do!
Periodontal Disease? Brushing teeth is vital to prevent doggy breath, but not enough to ensure animal health and well-being
Ezabenlimab
Ezabenlimab, PD-1 antibody
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Our Twitter Community Guidelines
Our Twitter Community Guidelines
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Vaccine prevent calf diarrhea
Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
PRRS vaccine celebrates 25 years in Europe
Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Career tips from our Global Head of HR
Sven Sommerlatte explains how important it is to reflect on the personal career strategy.
Life stages of cats
Cats go through different stages of life. Knowing more about these stages can help you understand your cat’s medical needs better.
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Classical Swine Fever live vaccine approved in China
Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
EMPRISE-Study
EMPRISE-Study
Soaring to save lives
Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline